• Increased levels of microRNA-320 in blood serum and plasma is associated with imminent and advanced lung cancer 

      Nøst, Therese Haugdahl; Skogholt, Anne Heidi; Urbarova, Ilona Halva; Mjelle, Robin; Paulsen, Erna-Elise; Dønnem, Tom; Andersen, Sigve; Markaki, Maria; Røe, Oluf Dimitri; Johansson, Mikael; Johansson, Mattias; Grønberg, Bjørn Henning; Sandanger, Torkjel M; Sætrom, Pål (Peer reviewed; Journal article, 2022)
      Lung cancer (LC) incidence is increasing globally and altered levels of microRNAs (miRNAs) in blood may contribute to identification of individuals with LC. We identified miRNAs differentially expressed in peripheral blood ...
    • Increased levels of microRNA-320 in blood serum and plasma is associated with imminent and advanced lung cancer 

      Nøst, Therese Haugdahl; Skogholt, Anne Heidi; Urbarova, Ilona Halva; Mjelle, Robin; Paulsen, Erna-Elise; Dønnem, Tom; Andersen, Sigve; Markaki, Maria; Røe, Oluf Dimitri; Johansson, Mikael; Johansson, Mattias; Grønberg, Bjørn Henning; Sandanger, Torkjel M; Sætrom, Pål (Peer reviewed; Journal article, 2022)
      Lung cancer (LC) incidence is increasing globally and altered levels of microRNAs (miRNAs) in blood may contribute to identification of individuals with LC. We identified miRNAs differentially expressed in peripheral blood ...
    • Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies 

      Melvold, Katrine; Giliberto, Mariaserena; Karlsen, Linda; Ayuda-Duran, Maria del Pilar; Hanes, Robert; Holien, Toril; Enserink, Jorrit; Brown, Jennifer R.; Tjønnfjord, Geir Erland; Tasken, Kjetil; Skånland, Sigrid Strand (Peer reviewed; Journal article, 2021)
      Most patients with chronic lymphocytic leukemia (CLL) initially respond to targeted therapies, but eventually relapse and develop resistance. Novel treatment strategies are therefore needed to improve patient outcomes. ...